Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/yd.207 | DOI Listing |
Methods Mol Biol
May 2019
AntiCancer, Inc., San Diego, CA, USA.
The elevated methionine (MET) requirement of cancer cells is termed MET dependence and is possibly the only known general metabolic defect in cancer. Targeting MET by recombinant methioninase (rMETase) can arrest the growth of cancer cells in vitro and in vivo due to their elevated requirement for MET. rMETase can also potentiate chemotherapy drugs active in S phase due to the selective arrest of cancer cells in S/G phase during MET restriction (MR).
View Article and Find Full Text PDFNew Dir Youth Dev
June 2007
Department of Psychology, Clark University.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!